Biochemical studies of the effect of arsenic trioxide on Ehrlich ascites tumor: Thesis Abstract

Document Type : Essay Abstract

Authors

1 Biochemistry division, chemistry department, faculty of science, Tanta university , Egypt

2 Professor of Biochemistry Biochemistry Section, Chemistry Department, Faculty of Science, Tanta University

3 Professor of Medical Biochemistry, Faculty of Medicine Tanta University

4 Lecturer of Biochemistry Biochemistry Section, Chemistry Department, Faculty of Science Tanta University

Abstract

Thesis Abstract
Hexokinase 2 enzyme catalyzes the rate-limiting step in glycolysis. It is overexpressed in several carcinomas including breast cancer to sustain energy for rapidly dividing cells and associates with chemoresistance. However, impact of chemo drugs alone or in combination on hexokinase activity and autophagic cell death is unclear. Arsenic trioxide (As2O3) (ATO) is a metalloid with potent antineoplastic effects in several types of cancer especially acute promyelocytic leukemia and breast cancer. Due to the cytotoxicity and low efficacy of ATO when it is used alone, a combination of ATO with other chemotherapeutic drugs may provide a rational basis for novel therapeutic combinations. Despite these efforts, the specific cellular events that account for differential effects of ATO on cancer cells’viability and the possible therapeutic combinations remain to be well‐defined. In this report, we used an in vivo murine adenocarcinoma model to validate the effects of As2O3 and cisplatin on hexokinase activity and autophagic cancer cell death. We found that the two drugs inhibit hexokinase activity and induceautophagic marker, beclin 1 expression. Interestingly, combining As2O3 with cisplatin synergistically enhanced these effects and alleviated oxidative stress often encountered in As2O3 treatment. Altogether, our data provide direct evidence that inhibition of hexokinase activity and induction of autophagic cell death are mediating the antineoplastic effects of As2O3 and cisplatin. Our findings raise the potential of combiningAs2O3 with cisplatin as an approach to augment cisplatin-induced cell death and combat cisplatin chemo-resistance in cancer.

Keywords

Main Subjects

Egyptian Journal of Cancer and Biomedical Research
Volume 5, Issue 1.1 - Serial Number 1
Special Issue: Thesis Abstracts
May 2021
Pages 26-26

Files

Share

How to cite

Statistics